<DOC>
	<DOCNO>NCT01220856</DOCNO>
	<brief_summary>Inhibition CXCL8 activity might represent relevant therapeutic target prevent injury occur pancreatic islet transplantation . Reparixin novel specific inhibitor CXCL8 . This study design explore efficacy reparixin prevent graft dysfunction islet transplantation type 1 diabetes patient ( T1D ) .</brief_summary>
	<brief_title>Reparixin Pancreatic Islet Transplantation</brief_title>
	<detailed_description>Pancreatic islet transplantation become feasible option treatment T1D offer advantage whole pancreas transplantation . However date insulin independence obtain case patient receive repeated infusion several donor . A non-specific immune response , mediate predominantly innate inflammatory process , couple specific cellular immune response , possibly promote early inflammation , play major role loss transplant islet liver . PMNs find predominant cell type infiltrate vitro islet . In regard , CXCL8 show express human islet could play crucial role trigger inflammatory reaction . Thus , CXCL8 might represent relevant therapeutic target prevent early graft failure . The efficacy reparixin improve graft outcome mouse model intrahepatic islet transplantation , well safety show human phase 1 2 study , provide rationale clinical study aim evaluate effect reparixin prevent graft dysfunction islet transplantation T1D patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Inclusion criterion : Ages 1865 year , inclusive . Patients eligible pancreatic islet transplantation base local accepted practice guideline . This include least : ) clinical history compatible T1D insulindependence &gt; 5 year ; b ) undetectable stimulate ( arginine MMTT ) Cpeptide level ( &lt; 0.3 ng/mL ) 12 month transplant . Sites comply additional stringent criterion locally accept , per centre practice . Patients adequate renal reserve per calculate creatinine clearance ( CLcr ) &gt; 60 mL/min accord CockcroftGault formula ( 1976 ) . Planned intrahepatic islet transplantation alone nonliving donor brain death . Planned infusion 4000 7000 islet equivalent ( IEQ ) /kg body weight . Patients willing able comply protocol procedure duration study , include schedule followup visit examination . Patients give write informed consent , prior studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Exclusion criterion : Recipients previous transplant , except recipient previous pancreatic islet transplantation fail , immunosuppression since least 1 year negative antiHLA . Recipients islet nonheart beat donor . A body mass index &gt; 30 kg/m2 patient weight &lt; 45 kg . Pretransplant average daily insulin requirement &gt; 1 IU/kg/day . Pretransplant HbA1c &gt; 11 % . Patients hepatic dysfunction define increase ALT/AST &gt; 3 x ULN increase total bilirubin &gt; 3mg/dL [ &gt; 51.3 micromol/L ] ) . Patients receive treatment medical condition require chronic use systemic steroid . Treatment antidiabetic medication insulin within 4 week transplant . Use investigational agent within 4 week enrolment . Hypersensitivity : ibuprofen one non steroidal antiinflammatory drug medication belong class sulfonamide , sulfamethazine , sulfamethoxazole , sulfasalazine , nimesulide celecoxib . Pregnant breastfeeding woman ; unwillingness use effective contraceptive measure ( female male ) . Sites comply additional exclusion criterion locally accept , per centre practice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Islet transplantation</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
</DOC>